Suven Pharmaceuticals Limited

Overview

Suven Pharmaceuticals Limited is an India-based pharmaceutical company that operates in the field of contract research and manufacturing services (CRAMS) with an emphasis on developing innovative therapies. As a prominent player in the pharmaceutical industry, Suven Pharmaceuticals focuses on discovering, developing, and commercializing high-quality molecules in the Central Nervous System segment.

Therapeutic areas

API / Drug Master Files

Suven Pharmaceuticals Limited holds 12 active (12 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• IRON SUCROSE COMPLEXActive2023-09-29
• ISOSULFAN BLUEActive2022-07-16
• DANOFLOXACIN MESYLATEActive2022-03-19
• METYROSINE USPActive2020-02-04
• GLYCOPYRRONIUM TOSYLATEActive2019-07-30
• ENTACAPONE USPActive2018-12-13
• DOXOFYLLINEActive2012-12-27
• FENOPROFEN CALCIUM USPActive2007-04-26
• (R)-(-)-5-(2-AMINOPROPYL)-2-METHOXYBENZENE SULPHONAMIDE HYDROCHLORIDE DRUG INTERMEDIATEActive2006-04-29
• 2-(2-ETHOXY PHENOXY) ETHYL BROMIDE - DRUG INTERMEDIATEActive2006-04-07
• ENTACAPONEActive2006-01-06
• GABAPENTIN USPActive2003-12-29

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Suven Pharmaceuticals Limited in our records. PharmaTek screens the full directory against live FDA enforcement data.